Base editing screens of PARP1 and PARP2 in the presence of olaparib or niraparib reveal drug-sensitizing and drug resistance variants. Comparison of gRNA z -scores for the control treated arm, olaparib-treated or niraparib-treated arm versus plasmid library is plotted against the amino acid position. Predicted amino acid editing consequences are labeled for drug resistance variants. The position of the catalytic domain of PARP1 and PARP2 is shown. Screening data are the average of two independent screens performed on separate days.
